Product Information
ETRAVIRINE 200 MG TABLET is a generic product labeled by Bionpharma Inc., priced at $9.9434 per EA under NDC 69452025517. Its NADAC has been published 35 times since Feb 4, 2026.
FDA first approved this application on Oct 2, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
200 mg/1
Manufacturer
Bionpharma Inc.NDC
69452025517
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ETRAVIRINEApproval Type
Generic (ANDA)
FDA Application
ANDA219152FDA Approved
10/2/2025
TE Code
AB
On Market Since
1/1/2026
Pharmacological Classes
Price Statistics
The NADAC for ETRAVIRINE 200 MG TABLET has been published 35 times since Feb 4, 2026, and over the history we have for it it has declined 15.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $9.9434 per EA |
|---|---|
| All-time high | $11.7118 (Feb 11, 2026) |
| All-time low | $9.9434 (Sep 23, 2026) |
| 52-week high | $11.7118 |
| 52-week low | $9.9434 |
| Median price | $11.3233 |
| Average price | $11.2552 |
| Largest weekly change | -7.8% (Sep 23, 2026) |
| Weeks tracked | 35 |
| Tracking since | Feb 4, 2026 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Bionpharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
etravirine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ETRAVIRINE 200 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ETRAVIRINE 200 MG TABLET, manufactured by Bionpharma Inc., is $9.9434 per EA (NDC 69452025517), effective Sep 30, 2026.
How has the price of ETRAVIRINE 200 MG TABLET changed over time?
Over the history we have for it, the NADAC for ETRAVIRINE 200 MG TABLET has declined 15.1%. It has been tracked across 35 weekly CMS publications since Feb 4, 2026.
What are the highest and lowest recorded NADAC prices for ETRAVIRINE 200 MG TABLET?
Since Feb 4, 2026, the NADAC for ETRAVIRINE 200 MG TABLET has ranged from a low of $9.9434 (Sep 23, 2026) to a high of $11.7118 (Feb 11, 2026), with a median of $11.3233 per EA.
Are there cheaper alternatives to ETRAVIRINE 200 MG TABLET?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ETRAVIRINE 200 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures ETRAVIRINE 200 MG TABLET?
ETRAVIRINE 200 MG TABLET (NDC 69452025517) is labeled by Bionpharma Inc., and CMS classifies it as a generic product.